Doc Generici (PRIVATE.DOCG)

Overall impact
B (62)

Commentary

Doc Generici is a strong overall performer. With a 'B' rating of 62.1 for overall impact (68th percentile compared to all companies), Doc Generici ranks 162nd out of 245 industry peers, behind Agios Pharmaceuticals, Pharmaron Beijing H, PharmaZell and 158 others, and ahead of Catalyst Pharmaceuticals, Merck, Akorn and 80 others. On top material causes for Doc Generici's industry (Pharmaceuticals), Doc Generici performs well in Child and Maternal Health (90.8 score), Disease Eradication (91.6), Accountable Institutions (86.8) and 30 other causes where it received an 'A' score and performs poorly in Equal Pay and Opportunity (12.8 score), Reduced Use of tobacco (38.7), Equal Pay and Opportunity (12.8) and 9 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.DOCG
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1996
Employees
189
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Lombardy, Italy
Share classes
PRIVATE.DOCG
Doc Generici
Description
Manufacturer and wholesaler of generic pharmaceutical products intended for cardiovascular, gastrointestinal, metabolism and neurological treatments. The company provides drugs for the treatment of common medical conditions with a broad product portfolio with proven efficacy, enabling patients to get inexpensive yet effective medication for treating a wide variety of diseases.
Material causes
Ethos considers the following causes material for Doc Generici, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.